Page last updated: 2024-11-08

2-hydroxyestrone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-hydroxyestrone: catechol estrogen which is a major metabolite of estradiol in man & animals; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-hydroxyestrone : A 2-hydroxy steroid that is estrone substituted by a hydroxy group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID440623
CHEMBL ID1627343
CHEBI ID1156
SCHEMBL ID222517
MeSH IDM0083803

Synonyms (27)

Synonym
2,3-dihydroxy-estra-1,3,5(10)-trien-17-one
LMST02010032
2,3-dihydroxyestra-1,3,5(10)-trien-17-one
CHEBI:1156 ,
estra-1,3,5(1)-trien-17-one, 2,3-dihydroxy-
catecholestrone
362-06-1
C05298
2-hydroxyestrone
(8r,9s,13s,14s)-2,3-dihydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-one
2-hydroxy estrone
CHEMBL1627343
unii-uqs3a06ily
ccris 9276
uqs3a06ily ,
SCHEMBL222517
AKOS030254485
2-ohe1
(8r,9s,13s,14s)-2,3-dihydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6h-cyclopenta[a]phenanthren-17(14h)-one
DTXSID80904315
Q27105413
2-hydroxyestrone 100 microg/ml in acetonitrile
estra-1,3,5(10)-trien-17-one, 2,3-dihydroxy-; 2,3-dihydroxyestra-1,3,5(10)-trien-17-one; 2-hydroxyestrone; catecholestrone
HY-113251
CS-0059416
PD151132
(3as,3br,9bs,11as)-7,8-dihydroxy-11a-methyl-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-one

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" This study demonstrates that smoking exerts a powerful inducing effect on the 2-hydroxylation pathway of estradiol metabolism, which is likely to lead to decreased bioavailability at estrogen target tissues."( Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking.
Bradlow, HL; Fishman, J; Hershcopf, RJ; Michnovicz, JJ; Naganuma, H, 1986
)
0.27

Dosage Studied

ExcerptRelevanceReference
" As suggested by previous studies with quinone metabolites of benzene, the catechol estrogen metabolite 2-OH estrone was significantly more potent than the parent compound at suppressing lymphocyte functions in vitro; however, dosing regimens of 2-OH estrone that suppressed blastogenic response in vivo failed to inhibit nonspecific cell-mediated growth inhibition."( Modulation of nonspecific cell-mediated growth inhibition by estrogen metabolites.
Patterson, RM; Pfeifer, RW, 1985
)
0.27
" 16alpha-OHE(1) increased uterine weight in a dose-response manner to values that did not differ from rats treated with E(2)."( Tissue-selective effects of continuous release of 2-hydroxyestrone and 16alpha-hydroxyestrone on bone, uterus and mammary gland in ovariectomized growing rats.
Lotinun, S; Turner, RT; Westerlind, KC, 2001
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
2-hydroxy steroidAny hydroxy steroid carrying a hydroxy group at position 2.
catecholsAny compound containing an o-diphenol component.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Estrone Metabolism1622
Biochemical pathways: part I0466
Estrogen metabolism025

Bioassays (9)

Assay IDTitleYearJournalArticle
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID55148The compound was tested in vitro for its ability to initiate DNA replication1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Effect of steroids on DNA synthesis in an in vitro replication system: initial quantitative structure-activity relationship studies and construction of a non-estrogen receptor pharmacophore.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (185)

TimeframeStudies, This Drug (%)All Drugs %
pre-199070 (37.84)18.7374
1990's45 (24.32)18.2507
2000's44 (23.78)29.6817
2010's22 (11.89)24.3611
2020's4 (2.16)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.84 (24.57)
Research Supply Index5.37 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index30.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials21 (10.88%)5.53%
Reviews10 (5.18%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other162 (83.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]